Infection in cancer patients: A continuing association

The American Journal of Medicine

Volumn 81, Issue 1 SUPPL. 1, 1986, Pages 11-26

  Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZLOCILLIN; AZTREONAM; CARBENICILLIN; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFSULODIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CILASTATIN; CISPLATIN; CLAVULANIC ACID; CLINDAMYCIN; CLOTRIMAZOLE; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; CYTOSTATIC AGENT; FLUCYTOSINE; GENTAMICIN; IMIPENEM; KETOCONAZOLE; LATAMOXEF; MENADIONE; METICILLIN; METRONIDAZOLE; MEZLOCILLIN; MICONAZOLE; NAFCILLIN; NETILMICIN; OXACILLIN; PIPERACILLIN; PNEUMOCOCCUS VACCINE; SISOMICIN; SULFAMETHOXAZOLE; TICARCILLIN; TOBRAMYCIN; TRIMETHOPRIM; VANCOMYCIN;

ADVERSE DRUG REACTION; BACTERIAL INFECTION; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG THERAPY; FUNGUS; GRAM NEGATIVE BACTERIUM; GRANULOCYTE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MICROORGANISM; MYCOSIS; POLYMORPHONUCLEAR GRANULOCYTE COUNT; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; SURVEY; THERAPY;

ANTIBIOTICS; ANTINEOPLASTIC AGENTS; FEVER; HUMAN; IMMUNOSUPPRESSION; INFECTION; NEOPLASMS; NEUTROPENIA;

EID: 0022520999     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(86)90510-3     Document Type: Article

References (71)

1. Clostridium septicum infections and malignancy
2. Central nervous system infection in patients with cancer
3. Prophylaxis of oropharyngeal candidiasis with clotrimazole
4. Capnocytophaga sepsis: a newly recognised clinical entity in granulocytopenic patients
5. Experience with the subcutaneous cerebrospinal-fluid reservoir
6. CSF infections complicating the management of neoplastic meningitis
7. Long-term analysis of cerebrospinal fluid shunt infections
8. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy
9. Increasing incidence of gram-positive sepsis in cancer patients
10. Septic phlebitis: a neglected disease
11. Hickman catheter infections in patients with malignancies
12. Pseudomonas bacteremia: retrospective analysis of 410 episodes
13. Infections in hairy cell leukemia
14. Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia
15. Infectious complications of bone marrow transplantation
16. Effects of cytotoxic drugs and immunosuppressive agents on the immune system
17. Corticosteroids and infectious diseases
18. Risk of severe infection in patients with Hodgkin's disease or lymphoma after diagnostic laparotomy and splenectomy
19. Herpes zoster-varicella infection and lymphoma
20. Nosocomial respiratory infections with gram-negative bacilli
21. Epidemiological studies of Pseudomonas species in patients with leukemia
22. Patterns of oropharyngeal and fecal flora in patients with acute leukemia
23. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
24. Quantitative relationship between degree of myelosuppression and infection in patients with metastatic breast cancer (MBC)
25. Clinical presentation of infection in granulocytopenic patients
26. Gram-negative bacillary pneumonia in the compromised host
27. Randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies
28. Causes of death in acute leukemia
29. Fever and infection in leukemic patients
30. Use of gamma globulin in infection in acute leukemia patients
31. The effect of adrenal corticosteroid therapy on infections in acute leukemia
32. Infections in cancer patients—results with gentamicin sulfate therapy
33. Therapeutic trials with tobramycin
34. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trial
35. A randomized comparative trial of three aminoglycosides: comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies
36. Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer
37. Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients
38. Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin
39. Rational basis for the choice of regimens for empirical therapy of sepsis in granulocytopenic patients
40. Antibiotic combinations for infections in neutropenic patients: evaluation of carbenicillin plus either cephalothin or kanamycin
41. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer
42. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients
43. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients
44. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients
45. Gram-negative infection in cancer: study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin
46. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients
47. A randomized trial of moxalactam versus tobramycin plus ticarcillin (T + T) in 50 febrile neutropenic patients
48. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients
49. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia
50. Aztreonam + vancomycin (± amikacin) versus moxalactam + ticarcillin for the empiric treatment of neutropenic cancer patients
51. Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa
52. Antibiotic synergy in experimental infections with Pseudomonas. II. The effect of carbenicillin, cephalothin, or cephanone combined with tobramycin or gentamicin
53. Clinical significance of in vitro synergism between antibiotics in gram-negative infections
54. Antimicrobial synergism in the therapy of gram-negative rod bacteremia
55. Significance of antimicrobial synergism for the outcome of gram-negative sepsis
56. Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer
57. Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients: a prospective, randomized, double-blind study
58. Novel resistance selected by the new expanded-spectrum cephalosporins: a concern
59. Therapy of neutropenic rats infected with Pseudomonas aeruginosa
60. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections
61. Aspergillosis and mucormycosis
62. Disseminated moniliasis in the adult
63. Systemic candidiasis in cancer patients
64. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
65. Management of fever of unknown origin in cancer patients with neoplasms and neutropenia
66. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
67. White blood cell transfusions for control of infections in neutropenic patients
68. Normal granulocyte transfusion therapy
69. Filtration leukopheresis for granulocyte transfusion therapy
70. Granulocyte transfusions: a controlled study in patients with acute non-lymphocytic leukemia